Annexon lays out more GA drug data; Okyo Pharma pulls back public offering
In May, Annexon’s drug candidate ANX007 did not prove better at reducing the lesion growth in a leading cause of blindness. Now more data have …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
